R&D The post-Covid New Normal: a golden opportunity for the NHS? I recently had the pleasure of attending the PING Conference 2022, which had the tagline of ‘
Views & Analysis Bureaucracy and duplication: the reality of the PPRS Has the PPRS delivered on the aim of reducing bureaucracy and duplication?
Views & Analysis UK pharma denied legal challenge to drugs bill cap - updated Rejection of legal challenge an embarrassing blow, and means NHS England free to introduce new budget curbs.
Views & Analysis Improved access? The reality of the PPRS Keeping the UK branded medicines bill within affordable limits - has PPRS delivered?
Views & Analysis Creating headroom: can cutting spend on low-value prescripti... Can reducing NHS spending on 'low-value' prescriptions help fund new drugs?
R&D Reuters Pharma USA 2024 – Meruno Perugini Innovation in pharma comes in many forms, but at the end of the day what the industry cares about is results.
Digital Fixing clinical trial data management It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.